Antitumor agent-207

Antitumor agent-207 is a Pt (IV) -NO prodrug with high lipid solubility, good stability, and excellent tumor targeted release ability. Antitumor agent-207 has significant anti proliferative activity in various cells such as TE-1 (IC50 = 1.79 μM), TE-10 (IC50 = 1.95 μM), KYSE-30 IC50 = 5.99 μM), KYSE-520 (IC50 = 5.53 μM) cells. Antitumor agent-207 can significantly enhance intracellular Pt accumulation and DNA platformization levels, and effectively release NO. Antitumor agent-207 can be used for research on cancers such as esophageal cancer[1].

Product Specifications

UNSPSC

12352005

Target

Drug Metabolite

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[O-]/[N+](N1CCN(C(CCC(O[Pt]([NH3])([NH3])(Cl)(Cl)OC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=O)=O)=O)CC1)=N\OCC#C

Molecular Formula

C26H32Cl2F3N7O7Pt

Molecular Weight

877.56

References & Citations

[1]Qian Z, et al. Lipophilic integrated bioorthogonal self-catalyzed nitric oxide donor-platinum (IV) prodrugs for enhanced antitumor efficacy against esophageal cancer. Eur J Med Chem. 2026 Jan 5;301:118221.